BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1046 related articles for article (PubMed ID: 20370920)

  • 1. Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
    Kinzer MH; Chand K; Basri H; Lederman ER; Susanti AI; Elyazar I; Taleo G; Rogers WO; Bangs MJ; Maguire JD
    Malar J; 2010 Apr; 9():89. PubMed ID: 20370920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
    Mohapatra PK; Sarma DK; Prakash A; Bora K; Ahmed MA; Sarma B; Goswami BK; Bhattacharyya DR; Mahanta J
    PLoS One; 2014; 9(9):e105562. PubMed ID: 25184337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.
    Tekete M; Djimde AA; Beavogui AH; Maiga H; Sagara I; Fofana B; Ouologuem D; Dama S; Kone A; Dembele D; Wele M; Dicko A; Doumbo OK
    Malar J; 2009 Feb; 8():34. PubMed ID: 19245687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal.
    Ranjitkar S; Schousboe ML; Thomsen TT; Adhikari M; Kapel CM; Bygbjerg IC; Alifrangis M
    Malar J; 2011 Apr; 10():75. PubMed ID: 21457533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia.
    Schunk M; Kumma WP; Miranda IB; Osman ME; Roewer S; Alano A; Löscher T; Bienzle U; Mockenhaupt FP
    Malar J; 2006 Jul; 5():54. PubMed ID: 16817953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.
    Fryauff DJ; Sumawinata I; Purnomo ; Richie TL; Tjitra E; Bangs MJ; Kadir A; Ingkokusumo G
    Am J Trop Med Hyg; 1999 Apr; 60(4):542-6. PubMed ID: 10348226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic mutations in Plasmodium falciparum and Plasmodium vivax dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in Vanuatu and Solomon Islands prior to the introduction of artemisinin combination therapy.
    Gresty KJ; Gray KA; Bobogare A; Wini L; Taleo G; Hii J; Cheng Q; Waters NC
    Malar J; 2014 Oct; 13():402. PubMed ID: 25311473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia.
    Mekonnen SK; Aseffa A; Berhe N; Teklehaymanot T; Clouse RM; Gebru T; Medhin G; Velavan TP
    Malar J; 2014 Jun; 13():244. PubMed ID: 24964730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia.
    Fryauff DJ; Leksana B; Masbar S; Wiady I; Sismadi P; Susanti AI; Nagesha HS; Syafruddin ; Atmosoedjono S; Bangs MJ; Baird JK
    Ann Trop Med Parasitol; 2002 Jul; 96(5):447-62. PubMed ID: 12194705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.
    Jovel IT; Mejía RE; Banegas E; Piedade R; Alger J; Fontecha G; Ferreira PE; Veiga MI; Enamorado IG; Bjorkman A; Ursing J
    Malar J; 2011 Dec; 10():376. PubMed ID: 22183028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.
    Marfurt J; Müeller I; Sie A; Maku P; Goroti M; Reeder JC; Beck HP; Genton B
    Am J Trop Med Hyg; 2007 Nov; 77(5):947-54. PubMed ID: 17984359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine.
    Barnadas C; Tichit M; Bouchier C; Ratsimbasoa A; Randrianasolo L; Raherinjafy R; Jahevitra M; Picot S; Ménard D
    Malar J; 2008 Feb; 7():35. PubMed ID: 18302746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh.
    van den Broek IV; van der Wardt S; Talukder L; Chakma S; Brockman A; Nair S; Anderson TC
    Trop Med Int Health; 2004 Jun; 9(6):680-7. PubMed ID: 15189458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.
    Mula P; Fernández-Martínez A; de Lucio A; Ramos JM; Reyes F; González V; Benito A; Berzosa P
    Malar J; 2011 Aug; 10():214. PubMed ID: 21810256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the efficacy of antimalarial medicines in India via sentinel sites: Outcomes and risk factors for treatment failure.
    Mishra N; Srivastava B; Bharti RS; Rana R; Kaitholia K; Anvikar AR; Das MK; Ghosh SK; Bhatt RM; Tyagi PK; Dev V; Phookan S; Wattal SL; Sonal GS; Dhariwal AC; Valecha N
    J Vector Borne Dis; 2016; 53(2):168-78. PubMed ID: 27353588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Plasmodium falciparum Pfcrt and Pfmdr1 alleles in settings with different levels of Plasmodium vivax co-endemicity in Ethiopia.
    Hailemeskel E; Menberu T; Shumie G; Behaksra S; Chali W; Keffale M; Belachew M; Shitaye G; Mohammed H; Abebe D; Ashine T; Drakeley C; Mamo H; Petros B; Bousema T; Tadesse FG; Gadisa E
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():8-12. PubMed ID: 31539706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications.
    Mubjer RA; Adeel AA; Chance ML; Hassan AA
    Malar J; 2011 Aug; 10():245. PubMed ID: 21854642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique.
    Enosse S; Magnussen P; Abacassamo F; Gómez-Olivé X; Rønn AM; Thompson R; Alifrangis M
    Malar J; 2008 Jul; 7():115. PubMed ID: 18590577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India.
    Srivastava P; Ratha J; Shah NK; Mishra N; Anvikar AR; Sharma SK; Das MK; Srivastava B; Valecha N
    Malar J; 2013 Jul; 12():247. PubMed ID: 23866298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study.
    Chaponda EB; Mharakurwa S; Michelo C; Bruce J; Chandramoha D; Matthew Chico R
    Malar J; 2021 Jan; 20(1):61. PubMed ID: 33482823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.